SCHEMBL3898593

SCHEMBL3898593

CCN(CC)C(=O)CC[O]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.67
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP8 P22894 1/20 0.44
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
ABCB11 O95342 1/20 0.38
CYP2E1 P05181 1/20 0.38
PTGS1 P23219 1/20 0.38
HTT P42858 1/20 0.38
GSDMD P57764 1/20 0.38
NPC1 O15118 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH2 P05091 1/20 0.34
TSPO P30536 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2327551 0.85 LMNA (0.78) LMNAMMP1MMP2MMP3MMP8
SCHEMBL2975892 0.84 LMNA (0.76) LMNAMMP1MMP2MMP3MMP8
SCHEMBL9570178 0.82 LMNA (0.73) LMNAMMP1MMP2MMP3MMP8
SCHEMBL3897637 0.81 LMNA (0.64) LMNAMMP1MMP2MMP3MMP8
SCHEMBL12174600 0.81 LMNA (0.64) LMNAMMP1MMP2MMP3MMP8
SCHEMBL3306771 0.80 LMNA (0.89) LMNAMMP1MMP2MMP3MMP8
SCHEMBL633287 0.80 LMNA (0.70) LMNAMMP1MMP2MMP3MMP8
SCHEMBL8880040 0.79 ALDH1A1 (0.61) LMNAMMP1MMP2MMP3MMP8
SCHEMBL3898597 0.78 LMNA (0.67) LMNAMMP1MMP2MMP3MMP8
SCHEMBL13630657 0.78 LMNA (0.84) LMNAMMP1MMP2MMP3MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521396-B2 Substituted (thioxo)carbonylaminophenyluracils BAYER CROPSCIENCE AG (DE) 2009-04-21 US claimed
US-20060089262-A1 Substituted (thioxo)carbonylamino phenyl uraciles BAYER CROPSCIENCE AG (DE) 2006-04-27 US claimed
EP-1503994-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES Bayer CropScience AG (DE) 2005-02-09 EP claimed
WO-2003093244-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES BAYER CROPSCIENCE AG (DE) 2003-11-13 WO claimed
EP-0832082-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1998-04-01 EP claimed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 WO claimed
CN-111630052-B Dihydroindazinone derivatives 第一三共株式会社 2023-04-18 CN disclosed
CN-114040966-A Method for producing insulin-producing cell using dihydroindolizinone derivative 国立大学法人东京工业大学 2022-02-11 CN disclosed
CN-111630052-A Dihydroindazinone derivatives 第一三共株式会社 2020-09-04 CN disclosed
US-7521396-B2 Substituted (thioxo)carbonylaminophenyluracils BAYER CROPSCIENCE AG (DE) 2009-04-21 US disclosed
US-20070225209-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES MYRIAD GENETICS, INCORPORATED (US) 2007-09-27 US disclosed
EP-1107958-B1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-08-16 EP disclosed
US-20060089262-A1 Substituted (thioxo)carbonylamino phenyl uraciles BAYER CROPSCIENCE AG (DE) 2006-04-27 US disclosed
EP-0200915-B1 AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-09-27 EP disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
US-4829058-A INHIBITORS OF BACTERIA, MYCOBACTERIA AND PLASMODIA DR. KARL THOMAE GMBH (DE) 1989-05-09 US disclosed
EP-0280951-A1 Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates Roche Diagnostics GmbH (DE) 1988-09-07 EP disclosed
EP-0239815-A1 Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1987-10-07 EP disclosed
EP-0236140-A2 Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-09-09 EP disclosed
EP-0200915-A1 Aminopropanol derivatives, process for their preparation, their use and medicines containing them Roche Diagnostics GmbH (DE) 1986-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225209-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND DISEASES CLN6, PMP22, PSEN2 LMNA 253/4885MMP1 2281/4885MMP2 3412/4885
US-20060089262-A1 Substituted (thioxo)carbonylamino phenyl uraciles NQO2, TYMP, DPYD LMNA 4639/4885MMP1 4158/4885MMP2 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.